OliX Pharmaceuticals, Inc is a biotechnology company specializing in developing RNAi-based therapeutics for respiratory, neurological, ocular, and hepatic diseases. OliX has developed proprietary RNA interference (RNAi) technology and is focused on developing locally administrable RNAi therapeutics for dermal, ophthalmic, and pulmonary diseases. The company has also secured GalNAc-asiRNA to target various liver diseases and is expanding its portfolio.

Headquarters
1014, 17, Daehak4-Ro, Yeongtong-Gu, Suwon-Si, Gyeonggi-Do
Suwon; Gyeonggi;

Contact Details: Purchase the Olix Pharmaceuticals, Inc. report to view the information.

Website: http://www.olixpharma.com

Basic Information

Total Employees:

Purchase the Olix Pharmaceuticals, Inc. report to view the information.

Outstanding Shares:

Purchase the Olix Pharmaceuticals, Inc. report to view the information.

Registered Capital:

Purchase the Olix Pharmaceuticals, Inc. report to view the information.

Financial Auditors:

Purchase the Olix Pharmaceuticals, Inc. report to view the information.

Incorporation Date:

February 26, 2010

Key Executives

Purchase this report to view the information.

Chief Executive Officer

Ownership Details

Purchase this report to view the information.

26.4%

Purchase this report to view the information.

5.8%

Purchase this report to view the information.

3.1%

Subsidiaries

Olix Us Inc

올릭스 주식회사

Company Performance

Financial values in the chart are available after Olix Pharmaceuticals, Inc. report is purchased.

Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service

Key Financial Highlights

Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.

Net sales revenue

-66.73%▼

Total operating revenue

-68.94%▼

Operating Profit/Loss (EBIT)

-110.76%▼

EBITDA

-80.89%▼

Net Profit/Loss for the Period

-112.85%▼

Total Assets

-30.71%▼

Total Equity

-63.3%▼

Operating Profit Margin (ROS)

-580.26%▼

Net Profit Margin

-604.24%▼

Return on Equity (ROE)

-182.15%▼

Debt/Equity

133.97%▲

Quick Ratio

-4.33%▼

Cash Ratio

-1.7%▼

Olix Pharmaceuticals, Inc. (South Korea)

Similar companies